Omnichannel Pharma: Why Most Strategies Fail Before Launch

Omnichannel pharma is the practice of coordinating patient, caregiver, and HCP touchpoints across digital and physical channels so that every interaction builds on the last, rather than starting from scratch. Done well, it closes the gap between what a brand says and what a person experiences when they actually need help. Done poorly, which is most of the time, it produces a sophisticated-looking stack of disconnected channels that patients and prescribers see right through.

The pharmaceutical industry has spent years talking about omnichannel transformation. The gap between the conversation and the execution remains wide, and the reasons are structural, not technological.

Why Pharma Has an Omnichannel Problem That Technology Cannot Fix

I have worked across 30 industries in 20 years of agency leadership. Pharma is one of the few where the internal structure of the client organisation is almost always the primary obstacle to effective marketing, more so than budget, regulation, or channel complexity. When I was running a performance marketing agency and managing relationships with large healthcare clients, the pattern was consistent: the brand team wanted one thing, the medical affairs team wanted something safer, the commercial team wanted something faster, and the digital team was trying to retrofit all of it into a CRM that had been chosen by procurement three years earlier.

That is not a technology problem. That is a governance problem. And no omnichannel platform resolves it.

The promise of omnichannel, in pharma as elsewhere, is that a person receives a consistent, contextually relevant experience regardless of which channel they use to interact with a brand. The reality in most pharma organisations is that each channel is owned by a different team, funded from a different budget, and measured against different KPIs. The patient sees one brand. The organisation operates like four.

If you want to understand what omnichannel is actually supposed to solve, and where it diverges from simply running multiple channels at once, the distinction I draw in integrated marketing vs omnichannel marketing is worth reading before you build a strategy. The difference matters more in pharma than almost anywhere else, because the consequences of getting it wrong are not just commercial. They affect patient behaviour and, by extension, outcomes.

The HCP Channel Is Not What Most Pharma Brands Think It Is

There is a version of pharma omnichannel that is almost entirely focused on healthcare professionals, built around rep visits, digital detailing, medical congress activity, and email nurture sequences. It is the version that most pharmaceutical companies have been trying to improve since COVID forced them off face-to-face detailing.

The problem with this model is not that it focuses on HCPs. HCPs are the primary prescribing decision-maker for most therapies, and that matters commercially. The problem is that most pharma brands treat the HCP channel as a content distribution problem when it is actually a relationship problem. Sending a cardiologist a personalised email sequence after they attended a webinar is not omnichannel. It is automated follow-up with better segmentation.

Genuine HCP omnichannel means that when a rep walks into a conversation, they know what the physician has already engaged with online, which clinical questions remain unanswered, and what the physician’s patient population looks like in terms of the condition being treated. It means the medical science liaison and the brand team are working from the same contact record and the same engagement history. That requires a data infrastructure that most pharma organisations have not built, and a willingness to share information across teams that most pharma organisations have not developed.

Semrush’s overview of omnichannel marketing makes a point that applies directly here: channel coordination is only as effective as the data model underneath it. In pharma, that data model has to account for compliance constraints, consent frameworks, and the fact that HCP contact preferences are not static. A physician who responded well to digital engagement during lockdown may now prefer in-person meetings again. The system has to reflect that.

Patient-Facing Omnichannel Is a Different Problem Entirely

Patient engagement in pharma operates under a different set of constraints and a different set of expectations than HCP engagement. Patients are not evaluating clinical evidence. They are trying to manage a condition, often while anxious, often while handling a healthcare system that feels opaque, and often while receiving conflicting information from multiple sources.

The brands that do patient-facing omnichannel well are the ones that have genuinely thought about what it feels like to be diagnosed with the condition they treat, and built their channel strategy around reducing that friction, not around maximising brand exposure. I have seen the difference from the inside. The clients who briefed us with a patient empathy map and a clear view of where the system was failing people produced better work, and better results, than the clients who briefed us with a reach target and a list of approved messages.

This connects to something I think about a lot in marketing more broadly. If a company genuinely improved the experience of every person who interacted with it, that alone would drive growth. Marketing is often used as a blunt instrument to prop up products or services that have more fundamental experience problems. In pharma, that tendency is particularly visible because the stakes are higher and the patient is less forgiving of a gap between what a brand promises and what it delivers.

The three-dimensional framework for thinking about customer experience that I outline in customer experience has three dimensions applies directly to pharma patient programmes. The functional dimension (does the treatment work and can I access it), the emotional dimension (do I feel supported and understood), and the social dimension (does this brand reflect my values and circumstances) all operate simultaneously. A patient support programme that nails the functional dimension but ignores the emotional one will see adherence drop at exactly the point where the treatment is most important.

Mailchimp’s guide to omnichannel personalisation covers the mechanics of building personalised experiences across channels, and the principles translate well to pharma patient programmes, with the obvious caveat that personalisation in a regulated environment requires a more careful approach to consent and data use than most DTC brands need to consider.

Compliance Is a Real Constraint. It Is Also a Convenient Excuse.

Every conversation about pharma marketing eventually arrives at compliance. And compliance is real. The regulatory environment for pharmaceutical communications is genuinely complex, varies by market, and carries consequences that most industries do not face. I am not dismissing it.

What I am saying, based on working with pharma clients for a significant part of my career, is that compliance is regularly invoked to avoid decisions that are actually strategic rather than regulatory. “We cannot do that because of compliance” is sometimes accurate. It is also sometimes a way of saying “we cannot agree internally on what we want to say, and compliance gives us a reason to delay.”

The pharma brands that have built effective omnichannel programmes have done so by treating compliance as a design constraint rather than a veto. They involve medical and regulatory teams early, they build compliant content frameworks that allow for personalisation within approved parameters, and they accept that some things will need to be cut. But they do not use the existence of a regulatory framework as a reason to produce generic, risk-averse communications that say nothing useful to anyone.

The best creative I have seen from pharma clients came from teams that were genuinely curious about what they were allowed to do, not teams that were focused on what they were not allowed to do. That is a mindset shift, not a compliance change.

The Data Infrastructure Question That Most Pharma Strategies Skip

Building an omnichannel strategy before you have a coherent data infrastructure is like designing a building before you have surveyed the ground. It produces plans that look credible until you try to implement them, at which point the gaps become expensive.

In pharma, the data infrastructure challenge is acute for several reasons. Patient data is subject to strict privacy regulation across every major market. HCP data is held in multiple systems, often including legacy CRM platforms, rep-managed databases, and third-party data providers that do not talk to each other. Consent management is complex, and the rules around what you can and cannot do with different categories of data vary by geography.

The brands that have made genuine progress on omnichannel have typically done one of two things. They have either invested in a unified data platform that brings together HCP and patient data under a single governance framework, or they have accepted that they cannot unify everything and have instead focused on making a smaller number of channels work extremely well together. Both approaches are legitimate. The one that consistently fails is the one that tries to claim omnichannel capability without having resolved the underlying data question.

The question of how AI fits into this data infrastructure is increasingly central to the conversation. The distinction between governed AI and autonomous AI in customer experience software is particularly relevant in pharma, where the stakes of an AI making an unsupervised decision about patient communication are higher than in most other sectors. Governed AI, where outputs are reviewed and constrained within defined parameters, is the only credible approach in a regulated healthcare environment right now.

Mailchimp’s omnichannel ecommerce framework is built for a different context, but the underlying logic around connecting data points across channels to build a coherent customer view is directly applicable to how pharma brands should be thinking about their CRM and engagement infrastructure.

What the Retail Media Parallel Teaches Pharma About Channel Ownership

There is an instructive parallel between what is happening in pharma omnichannel and what is happening in retail media. In both cases, brands are operating within ecosystems they do not fully control, trying to reach audiences who are being targeted by multiple parties simultaneously, and trying to build coherent experiences across channels where the data is fragmented and the attribution is imperfect.

The lessons from retail media, particularly around channel ownership and first-party data strategy, apply directly to pharma. The best omnichannel strategies for retail media share a common thread: brands that own their data relationships perform better than brands that rent them from intermediaries. In pharma, that means investing in owned patient support programmes, owned HCP portals, and owned data assets rather than relying entirely on third-party data providers and platform-owned audiences.

This is a longer-term investment than most pharma marketing budgets are structured to support. But the brands that have made it are now in a structurally better position than those that did not, particularly as third-party data availability continues to contract.

Measuring Omnichannel Effectiveness in a Regulated Environment

Measurement in pharma omnichannel is genuinely difficult, and I say that having managed hundreds of millions in ad spend across industries where measurement is already contentious. The challenge in pharma is not just attribution, though attribution across HCP and patient channels is complex enough. It is that the outcomes that matter most, prescription behaviour, adherence rates, patient outcomes, are often not directly accessible to the marketing team and are subject to their own privacy and reporting constraints.

What most pharma brands measure instead is a set of proxy metrics: HCP engagement rates, patient programme enrolment, digital content consumption, rep call effectiveness. These are useful, but they are not the same as measuring whether the omnichannel programme is actually driving the outcomes it is supposed to drive.

The most honest approach I have seen is to build a measurement framework that is explicit about what you can measure directly, what you can infer from proxy metrics, and what you cannot measure at all. That honesty is uncomfortable for clients who want clean attribution models, but it produces better decisions than a dashboard full of metrics that look precise but are actually measuring activity rather than impact.

Net Promoter Score is one of the tools that some pharma patient programmes have adopted as a proxy for experience quality. HubSpot’s guide to measuring NPS covers the mechanics well. In a pharma context, NPS is a blunt instrument, but it is better than measuring nothing, and it tends to surface the experience failures that matter most to patients in a way that engagement metrics alone do not.

Thinking about how other industries have structured their customer experience measurement can also be instructive. The food and beverage customer experience framework, for instance, offers a useful model for thinking about how touchpoints connect across awareness, consideration, and loyalty stages, even though the regulatory and clinical context in pharma is entirely different. The underlying logic of mapping experience against commercial outcomes is transferable.

Where Customer Success Fits in the Pharma Omnichannel Model

Patient support programmes are, in effect, a form of customer success function. They exist to ensure that patients who have been prescribed a treatment can access it, afford it, understand how to use it, and stay on it long enough to experience the benefit. When they work well, they drive adherence, reduce discontinuation, and generate the kind of patient experience that influences prescribing behaviour through word of mouth and patient advocacy.

When they are treated as a compliance checkbox or a post-launch afterthought, they produce the opposite: patients who feel unsupported, discontinue treatment, and associate the brand with the frustration of trying to handle a system that was not designed with them in mind.

The principles behind customer success enablement apply directly here. Giving the people who manage patient support programmes the tools, data, and authority to actually solve patient problems, rather than just log them, is the difference between a programme that retains patients and one that documents their departure. I have seen pharma clients spend significant budget on building patient support infrastructure and then under-resource the team responsible for running it. The infrastructure is not the product. The human interaction is.

Optimizely’s omnichannel marketing trends research highlights that the brands seeing the strongest omnichannel results are those that have connected their customer success functions to their marketing data. In pharma, that means patient support teams and brand teams sharing information about where patients are struggling, and using that information to improve both the support programme and the broader communications strategy.

If you are building or evaluating a pharma omnichannel strategy, the broader customer experience principles that underpin effective engagement are worth grounding yourself in before you get into channel-specific tactics. The channel decisions are secondary to the experience decisions, and in pharma more than most industries, getting the experience right is not optional.

The Honest Assessment of Where Most Pharma Brands Actually Are

Most pharma brands are not doing omnichannel. They are doing multichannel with better branding consistency than they had five years ago. That is not nothing, but it is not what the industry has been promising itself it would achieve.

The gap between the ambition and the execution is not primarily a technology gap. The platforms exist. The data capabilities exist, at least in principle. The gap is organisational. It is about whether the brand team, the medical team, the commercial team, and the digital team can agree on a shared model of who their patient or HCP is, what that person needs at each stage of their interaction with the brand, and how each channel contributes to meeting that need.

I have judged the Effie Awards, which means I have seen behind the curtain of a lot of marketing effectiveness claims. The pharma work that stands out is almost always the work where someone, usually a senior leader with enough authority to cut through the internal politics, made a clear decision about what the brand was trying to do for the person it was trying to reach, and built the channel strategy around that decision rather than around the existing organisational structure.

That is not a complicated insight. But it is a rare one in practice, and it is the thing that separates the pharma brands that are making genuine progress on omnichannel from the ones that are producing impressive-looking strategy decks and then implementing them as a series of disconnected channel initiatives.

Search Engine Journal’s analysis of personalisation fallout is a useful reminder that personalisation done without proper data governance and genuine relevance can backfire, creating experiences that feel intrusive rather than helpful. In pharma, where patient trust is both fragile and commercially essential, that risk is amplified. The goal is not to demonstrate that you know a lot about a patient. It is to use what you know to make their experience materially better.

About the Author

Keith Lacy is a marketing strategist and former agency CEO with 20+ years of experience across agency leadership, performance marketing, and commercial strategy. He writes The Marketing Juice to cut through the noise and share what works.

Frequently Asked Questions